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Background: In a cluster randomized trial (CRT) of a Vi polysaccharide vaccine against typhoid in the slums of
Kolkata we found evidence of vaccine herd protection. However, transmission of typhoid into clusters from the
outside likely occurred in this densely populated setting, which could have diminished our estimates of vaccine
herd protection.
Methods: Eighty clusters (40 in each arm) were randomised to receive a single dose of either Vi or inactivated
hepatitis A vaccine. We analysed protection for the entire cluster and for subclusters consisting of residents of
the innermost households.
Results: During 2 y of follow-up, total protection was 61% (95% CI 41 to 75), overall protection was 57% (95%
CI 37 to 71) and indirect protection was 44% (95% CI 2 to 69). Analyses of the innermost 75% and 50% of
households of the clusters showed similar ﬁndings. However, in the innermost 25%of households of the clusters,
total protection was 82% (95% CI 48 to 94) and overall protection was 66% (95% CI 27 to 84). There was not a
sufﬁcient sample size to demonstrate such a trend for indirect protection in these innermost households.
Conclusions: The ﬁndings suggest that analyses of the entire cluster may have led to underestimation of herd
protection against typhoid by Vi vaccine and that restriction of the analyses to the inner subclusters may have
led to a more accurate estimation of vaccine herd effects.
Keywords: cluster randomized trial, fried egg design, typhoid fever, vaccine effectiveness, Vi polysaccharide vaccine, Clinical
trial registration: ClinicalTrials.gov, NCT00125008.
Introduction
Typhoid fever, caused by Salmonella enterica serovar Typhi
(S. Typhi), remains an important cause ofmorbidity andmortality
in populations residing in low- and middle-income countries
(LMICs), with global estimates ranging between 11 and 21million
cases and 128 000 to 161 000 deaths annually.1,2 An injectable
Vi polysaccharide vaccine is safe and moderately effective,3,4
and has been licensed for persons ≥2 y of age.5 However, its
use in public health programmes has been limited despite a
recommendation for its use by theWHP Strategic Advisory Group
of Experts.5 Surveillance for typhoid in Guangxi, China after the
introduction of Vi vaccine without massive structural change in
the water sanitation and hygiene infrastructure for the general
population revealed near disappearance of the disease,6 raising
the possibility that the vaccine can elicit herd as well as direct
protection.
To address whether Vi vaccine confers herd as well as direct
protection against typhoid, we conducted a large-scale, cluster
randomized trial (CRT) of Vi vaccine given to persons ≥2 y of
age in Kolkata, India, where typhoid fever is endemic.7 Analysis
of typhoid in the clusters revealed evidence of herd protection.
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However, because transmission of typhoid into the clusters from
outside their perimeters likely occurred in this densely populated
urban setting, and because such transmissionwould be predicted
to depress estimates of vaccine herd protection, we decided
to reanalyse the trial data using the ‘fried egg’ approach. This
approach, in which only the innermost households of clusters
(the ‘yolk’) are analysed, with the residents outside the innermost
clusters (the ‘white’) serving as a buffer, has been claimed to
minimize biased estimates of herd protection due to inward
transmission.8 Herein we report the results of a reanalysis of the
trial,7 which suggests that inward transmission of typhoid likely
resulted in underestimates of Vi vaccine herd protection in our
original published analysis.
Methods
Study site
The trial was carried out in a portion of Ward 29 and all of Ward
30 in eastern Kolkata, a legally registered urban slum with a
population of about 62 000. A census of the de jure population
was undertaken prior to vaccination to enumerate members
of all households, including their geographical coordinates of
residence, and to collect the socio-economic and water and
sanitation status of each household. Each individual in the census
was assigned a unique study identiﬁcation number so that the
individual could be followed over the period of the study. The
census, together with household mapping, was used to deﬁne
80 contiguous geographical clusters that served as the units of
randomization.
Randomization of clusters
We divided the clusters into eight strata, deﬁned by study ward,
number of residentswhowere≤18 y of age at zero time (<200 vs
≥200 persons) and number of residents who were >18 y of age
(<500 vs ≥500 persons) (Figure 1), and randomized the clusters
in blocks of two within each stratum to create the Vi vaccine and
hepatitis A vaccine (HAV) arms of the trial.
Vaccination
Each dose of Vi vaccine (Typherix, GlaxoSmithKline) contained
25 μg of Vi polysaccharide. The control agent, inactivated HAV
(Havrix, GlaxoSmithKline), contained 720 IU of inactivated hep-
atitis A virus for children 2–18 y of age and 1440 IU for adults.
Each vaccine was administered by i.m. injection in a participant
and observer blinded fashion. The vaccines were administered
between 27 November and 31 December 2004. Residents ≥24
mo of age, without subjective or objective fever and not pregnant
or lactating, were eligible to receive vaccine after giving written
informed consent (guardian in case of minors). Vaccination was
done in project vaccination centres set up in each cluster.
Surveillance for enteric fever
Five project clinics (three in Ward 29 and two in Ward 30)
were established to conduct surveillance for febrile illnesses
and to refer patients with severe disease for their primary
care. Private medical care providers in the two study wards
were encouraged to refer their febrile patients to these study
clinics. Additionally, the emergency rooms, outpatient clinics
and inpatient wards of the two government hospitals serving
the study area monitored patients presenting with febrile
illnesses. Subjects from the study area presenting with a
history of at least 3 d of fever were examined by a study
physician, data on the subject’s history and physical ﬁndingswere
systematically recorded and a blood specimen was collected
for culture after obtaining verbal informed consent. Standard
biochemical and serological methods were used to identify S.
Typhi.9 Patients were identiﬁed in the surveillance sites with
the assistance of study census identiﬁcation cards carried by
patients and an onsite computerized database. Whenever a
blood culture yielded S. Typhi, a study team was dispatched
to the home of the patient within 7 d to verify that the
subject whose name had been given had indeed visited the
treatment site for care on the date noted in the surveillance.
Patients received antibiotic treatment following the national
guidelines.
Deﬁnitions
Zero time, the onset of follow-up, was the date of vaccination or,
for non-vaccinees, the median date of vaccination for vaccinees
in the cluster. A febrile episode comprised all treatment visits
for fever in which the recalled onset of fever for one visit was
within 14 d of presentation for the next earlier visit. An episode of
typhoid fever was a febrile episode in which S. Typhi was isolated
from at least one blood culture during the febrile episode. The
onset of the episode was the recalled onset of fever for the ﬁrst
treatment visit of the episode.
Deﬁning the yolk for the fried egg analytic approach
We used the fried egg approach to reanalyse the data for this
trial.8 With this approach we analysed Vi protection against
typhoid fever for the entire cluster, as well as for residents of
the innermost 75%, the innermost 50% and the innermost
25% of households (‘yolks’) of each cluster. A diagram of
these four fractions is shown in Figure 2. We hypothesized
that if estimates of Vi herd protection against typhoid had
been attenuated by the transmission of typhoid fever into
the clusters from the outside, this protection would be most
evident in the innermost households. To demarcate these
different sized yolks, we calculated the linear distance of each
household to the nearest cluster perimeter and sorted the
households in each cluster in ascending (furthest from to
closest to the nearest perimeter) order by distance. We then
assembled successive proportions of households, beginning with
the household furthest from the perimeter and proceeding
to include households progressively closer to the nearest
perimeter until the desired fraction of households was reached.
Before undertaking the analysis, we speciﬁed four fractions of
households for analysis: 25% (innermost yolk), 50%, 75% and
100% (outermost yolk including the entire cluster), referred to as
P25, P50, P75 and P100, respectively. Figure 3 shows households
that were included in analyses of overall Vi protection for the
P25 group.
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Figure 1. Diagrammatic presentation showing subjects’ distribution within strata and clusters.
Figure 2. Diagrammatic representation of the four fractions of the fried
egg approach.
Analytic strategies
As in our original analysis of this trial, the occurrence of blood
culture-proven typhoid fever constituted the primary outcome
for the trial.7 All measures of Vi vaccine protection against
culture-proven typhoid feverwere expressed as the proportionate
reduction of disease incidence ([1−hazard ratio of typhoid fever
in the Vi clusters versus the HAV clusters]×100%). We assessed
Vi vaccine herd protection as total, indirect and overall vaccine
protection. For assessment of total protection, protection directly
conferred to Vi vaccinees as well as additional herd protection
of Vi vaccinees, we compared rates of typhoid in Vi vaccine
recipients in the Vi clusters versus rates in HAV recipients in the
HAV clusters. For indirect protection, protection of non-vaccinees
against typhoid in the Vi clusters due to reduced person-to-
person transmission of typhoid in the Vi clusters, we compared
rates of typhoid among non-vaccinees in the Vi clusters versus
rates among non-vaccinees in the HAV clusters. And for overall
protection, protection of all members of the Vi-vaccinated
clusters due to direct protection of Vi vaccinees and additional
herd protection of Vi vaccinees and non-vaccinees, we compared
rates of typhoid among all residents of the Vi clusters versus
rates among all residents of the HAV clusters.10 If transmission
of typhoid into the clusters from the outside had occurred,
we hypothesized that estimates of Vi vaccine herd protection
should become more pronounced the longer the distance of the
household from the nearest perimeter. As in our earlier analysis,7
we limited our analyses to persons present at zero time and we
analysed each of thesemeasures of Vi protection after redeﬁning
the persons under analysis in the clusters as the P25, P50, P75
and P100 populations. In all analyses we evaluated Vi vaccine
protection against the ﬁrst episodes of typhoid fever having
onsets between 1 and 730 d after zero time, and for which a
home visit conﬁrmed that the person whose name was given
at the treatment centre had indeed sought care on the date of
presentation.
We evaluated the following a priori zero time variables as
potential confounding variables in analyses of vaccine protection:
age (years), sex (male vs female), religion (Hindu vs others),
ability of headof household to read andwrite (yes vs no),monthly
per capita household expenditure (<median vs ≥median),
ownership of at least one luxury item in household (yes vs no),
household use of a tube well or faucet for drinking water
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Figure 3. Distribution of study area households (entire study area in the left panel, close-up view of some of the clusters in the right panel) for analyses
of the P25 clusters. Note: The yellow dots are the households in the P25 clusters and the white dots represent other households in the entire cluster.
(yes vs no), cluster population density (<median vs ≥median),
ﬂush toilet in household (yes vs no), access to a speciﬁc place
for waste disposal in the household (yes vs no) and distance
of household to the nearest treatment centre (<median vs
≥median). Comparisons of these variables between treatment
arms employed generalized estimating equations to adjust
for membership in the randomized clusters, with the logit link
function for dichotomous variables and the identity link function
for dimensional variables.11
To estimate vaccine protection, we conducted survival analy-
ses, right-censoring individuals who died or migrated out before
the end of the follow-up period or the end of the follow-up
period, whichever came ﬁrst. We ﬁtted Cox proportional hazards
regression models for each of the redeﬁned yolks and each type
of Vi vaccine herd protection.12–14 These models were adjusted
for age at zero time, sex and the stratiﬁcation variables for
randomization, as well as variables found to be unequally dis-
tributed at p<0.05 in bivariate baseline comparisons of the arms
of the study, following the requirement for at least 10 events
per covariate to maximize the coverage of the CI of the esti-
mate from the regression model.15 HRs were estimated by expo-
nentiating the coefﬁcient for the Vi vaccine variable in these
models and vaccine protective effectiveness (PE) was estimated
as ([1−HR]×100%). SEs for the coefﬁcients were used to esti-
mate p-values and 95% CIs for the HRs. All statistical analy-
ses were performed using SAS version 9.4 (SAS Institute, Cary,
NC, USA).
Ethics
The institutional review boards of the International Vaccine
Institute, the National Institute of Cholera and Enteric Diseases,
India and the Indian Council of Medical Research approved the
protocol and monitored the progress of the study. Individual
written informed consent was obtained from all participants
or their guardians. There were no agreements regarding the
conﬁdentiality of the data between study sponsors and the
investigators.
Results
The assembly of subjects and outcomes for analysis has been
published previously.7 At zero time there were 62 756 residents in
the 80 trial clusters, ofwhom61280were age eligible for the trial.
A total of 18 869 individuals received the Vi vaccine and 18 804
individuals received the HAV. The two treatment groupswerewell
balanced at the individual level with respect to demographic,
socio-economic and water source and hygiene characteristics
(Tables S1–S12).
For analysis of overall Vi vaccine protection (protection of all
residents in the Vi clusters relative to all residents in the HAV
clusters) against typhoid fever, there were 62 756 individuals and
177 typhoid fever episodes in the P100 group (Table 1), 46 978
persons and 129 typhoid fever episodes in the P75 group, 31 216
persons and 87 episodes in the P50 group and 15 469 persons
and 36 episodes in the P25 group (Table 1). Correspondingly,
overall PE against typhoid fever was 57% (95% CI 37 to 71;
p<0.0001) for the P100 group, with similar values for the P75
group (PE 51% [95% CI 26 to 67]; p=0.0005) and P50 group (PE
51% [95% CI 21 to 70]; p=0.0032). Overall protection rose in the
P25 group to 66% (95% CI 27 to 84; p=0.005) (Table 1).
For evaluation of total protection (protection of Vi recipients
relative to HAV recipients), there were 37 673 individuals and 130
cases of typhoid fever in the P100 group, 28 014 individuals and
92 episodes of typhoid fever in the P75 group, 18 722 individuals
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Table 1. Overall, total and indirect protection by Vi vaccine against typhoid fever in the differently deﬁned clusters
Measures of
protection
Vi vaccine clusters HAV clusters
No. of
persons
No. of
cases
Rate/1000
person-years
No. of
persons
No. of
cases
Rate/1000
person-years
PEa (%) 95% CI (%) p-Value
P100 clusters
Overalla 31 075 50 0.84 31 681 127 2.10 57 37 to 71 <0.0001
Totalb 18 869 34 0.93 18 804 96 2.65 61 41 to 75 <0.0001
Indirectc 12 206 16 0.70 12 877 31 1.28 44 2 to 69 0.0429
P75 clusters
Overall 23 148 40 0.90 23 830 89 1.96 51 26 to 67 0.0005
Total 14 079 26 0.96 13 935 66 2.46 58 34 to 74 0.0002
Indirect 9060 14 0.82 9895 23 1.24 33 −30 to 64 0.2502
P50 clusters
Overall 15 566 27 0.91 15 650 60 2.01 51 21 to 70 0.0032
Total 9512 16 0.87 9210 46 2.59 62 32 to 78 0.0010
Indirect 6060 11 0.96 6440 14 1.16 14 −81 to 59 0.6897
P25 clusters
Overall 7767 9 0.60 7702 27 1.86 66 27 to 84 0.0054
Total 4914 4 0.42 4413 22 2.61 82 48 to 94 0.0016
Indirect 2840 5 0.93 3283 5 0.82 −14 −298 to 68 0.8427
aOverall protection for the P100, P75 and P50 clusters was adjusted for the variables used to stratify the clusters for randomization, age, religion,
living in a household with a monthly per capita expenditure above the median and living in a household with a longer distance to the nearest
treatment centre than the median. For the P25 clusters, it was adjusted only for the variables used to stratify the clusters for randomization.
bTotal protection for the P100 and P75 clusters was adjusted for the variables used to stratify the clusters for randomization, age, religion, living
in a household with a monthly per capita expenditure above the median and living in a household with a speciﬁc place for waste disposal. For the
P50 clusters it was adjusted for the variables used to stratify the clusters for randomization, age, religion and living in a household with amonthly
per capita expenditure above themedian. For the P25 clusters it was adjusted only for the variables used to stratify the clusters for randomization.
cIndirect protection for the P100 clusters was adjusted for the variables used to stratify the clusters for randomization, age and living in a
household with a longer distance to the nearest treatment centre. For the P75 clusters it was adjusted for the variables used to stratify the
clusters for randomization and age. For the P50 clusters it was adjusted only for the variables used to stratify the clusters for randomization. For
the P25 clusters, no variables were used to adjust the effectiveness.
and 62 episodes of typhoid fever in the P50 group and 9327
individuals and 26 episodes of typhoid fever in the P25 group
(Table 1). Estimates of total Vi vaccine protection against typhoid
fever were 61% (95% CI 41 to 75; p<0.0001) in the P100 group,
with similar estimates for the P75 (PE 58% [95% CI 34 to 74];
p=0.0002) and P50 (PE 62% [95% CI 32 to 78]; p=0.001) groups.
Again, protection rose in the P25 group (82% [95% CI 48 to 94];
p=0.0016).
In analyses of indirect vaccine protection (protection of non-
recipients of vaccine in the Vi clusters relative to non-recipients
of vaccine in the HAV clusters), there were 25 083 individuals
and 47 episodes of typhoid fever in the P100 group, 18 955
individuals and 37 episodes of typhoid fever in the P75 group,
12 500 individuals and 25 episodes of typhoid fever in the P50
group and 6123 individuals and 10 episodes of typhoid fever in
the P25 group (Table 1). Indirect protection against typhoid fever
was 44% (95%CI 2 to 69; p=0.0429) in the P100 group, 33% (95%
CI −30 to 64; p=0.25) in the P75 group (Table 1), 14% (95% CI
−81 to 59; p=0.69) in the P50 group and −14% (95% CI −298 to
68; p=0.8427) in the P25 group (Table 1).
Discussion
Although the conventional analysis of this CRT, in which entire
clusters were analysed, revealed clear evidence of herd protec-
tion by Vi vaccine, we believe that the estimatesmight have been
biased in a conservative direction due to likely transmission of
typhoid into the clusters in the densely populated urban setting
for the trial, as observed in a trial conducted in Bangladesh using
the oral cholera vaccine.16 When we attempted to remove the
effects of such transmission on estimates of Vi herd protection
by restricting the analysis to the innermost population of the
clusters (P25 group), we found a much higher level of total
Vi protection (82%) and a somewhat higher level of overall Vi
protection (66%) than observed in the analysis of the entire
cluster. While the point estimate of indirect Vi protection in the
central 25% of households of the clusters did not reveal a similar
trend, the wide conﬁdence limits surrounding the estimate (95%
CI −298 to 68%) did not exclude an increase and were limited
by a very small number of typhoid outcomes for this analysis.
However, it is not only that the indirect protection did not show
5
D
ow
nloaded from
 https://academ
ic.oup.com
/inthealth/advance-article-abstract/doi/10.1093/inthealth/ihz069/5586242 by guest on 20 N
ovem
ber 2019
M. Ali et al.
the expected increase due to a small number of outcome events
in the P25 group, but also the CI for total protection for the P100
and P25 groups overlapped. Since the P25 group was a subset of
the P100 group, there is no real statistical basis for comparing
the two groups. In aggregate, our ﬁndings are consistent with
our hypothesis that transmission of typhoid into the clusters
attenuated our original estimates of Vi herd protection and that
restriction of the analysis to the innermost households acted
to produce estimates of protection that were less affected by
this bias.
To a certain extent our studymight seem somewhat anachro-
nistic, as the fact that Vi polysaccharide vaccine is no longer
considered an attractive vaccine for control of typhoid fever in
endemic settings is attested to by Gavi’s decision not to support
the vaccine in its typhoid vaccine introduction programme.
Recently the WHO has prequaliﬁed for purchase by United
Nations agencies a Vi polysaccharide–tetanus toxoid conjugate
typhoid vaccine (Vi-TT) that is licensed in India. Compared with Vi
polysaccharide, this Vi conjugate vaccine is more immunogenic
and induces immunological memory.17 And Gavi has opened
a funding window that subsidizes LMICs meeting Gavi criteria
to acquire this vaccine for their public health programmes.
Nonetheless, our analysis has important implications for clinical
evaluations of this and other future Vi-conjugate vaccines, for
which CRTs will be needed to estimate their population-level
effectiveness, including vaccine herd protection, when deployed
in realistic public health programmes.
To provide evidence for policy deliberations about deployment
of the WHO-prequaliﬁed Vi-TT in urban slums of South Asian
cities, where typhoid often thrives, we are currently testing
this vaccine in a large cluster randomized effectiveness trial in
the urban slums of Dhaka, Bangladesh.18 Although the CRT is
considered the best design for measuring population-level
vaccine herd protection in an unbiased fashion,10 a caveat of
this assertion is that clusters are selected and deﬁned in such
a fashion that they represent self-contained epidemiological
units of transmission of typhoid. In practice, including at the ﬁeld
site for our ongoing CRT of Vi-TT in Dhaka, it will be uncommon
for selected clusters to meet this condition, and estimates of
vaccine herd protective effects may be diminished to the extent
that this assumption is violated.19 Buffer zones are commonly
used in CRTs to prevent transmission of the target pathogen and
diffusion of interventions between clusters. However, if typhoid is
transmitted from the surrounding buffer zones into the study
clusters, buffer zones will not necessarily safeguard against
this problem. Because it may be difﬁcult in advance to predict
whether such transmission will occur in a CRT of vaccines, a
conservative approach would be to use the fried egg analytic
approach to help safeguard against this bias, and our current
trial of Vi-TT is designed to anticipate the use of this analytic
approach.
The major limitation of using the fried egg approach is the
sample size required to achieve adequate power in the analysis.
Our analysis of the innermost population (P25) clearly had an
inadequate sample size and hence inadequate statistical power
to measure the indirect protection provided by Vi vaccine in
this setting. Thus use of the fried egg approach to analyse vac-
cine herd effects in CRTs requires consideration of the balance
between the increased cost associated with the larger sample
sizes of the clusters and the increased accuracy of estimation of
vaccine herd effects in the innermost clusters.
In conclusion, our reanalysis of the CRT of Vi polysaccharide in
Kolkata using the fried egg approach yielded evidence of higher
levels of certain types of Vi vaccine herd protection in the inner-
most populations of the randomized clusters compared with our
original analyses of entire clusters. These ﬁndings sound a note
of caution that CRTs of vaccinesmay underestimate vaccine herd
protection when epidemiological assumptions about transmis-
sion of the target pathogen are not fulﬁlled and underscore the
need to consider using the fried egg analytic approach at the
design stage of such CRTs.
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